Treatment of Providencia stuartii Sensitive to Meropenem
Yes, treat with meropenem - it is an appropriate and effective choice for Providencia stuartii infections when the organism demonstrates in vitro susceptibility, regardless of resistance to quinolones and aminoglycosides.
Rationale for Meropenem Use
Meropenem is FDA-approved for complicated skin/skin structure infections and intra-abdominal infections caused by susceptible gram-negative organisms 1. The drug demonstrates excellent activity against Providencia stuartii, with historical data showing meropenem inhibits 90% of P. stuartii isolates at ≤0.25 mg/L, and is 4-16 fold more active than imipenem against this species 2.
Key Supporting Evidence
Natural susceptibility patterns: P. stuartii is naturally sensitive to modern carbapenems including meropenem, despite being naturally resistant to older penicillins, cephalosporins, tetracyclines, sulfonamides, and fosfomycin 3. Your isolate's resistance to quinolones and aminoglycosides fits this expected pattern.
Clinical success: A recent case report documented successful treatment of a difficult P. stuartii periprosthetic joint infection using prolonged meropenem infusion, with no infection recurrence at 2-year follow-up 4.
Broad gram-negative coverage: Meropenem maintains activity against most aerobic gram-negative nosocomial pathogens and is considered among the most broadly active antibiotics for systemic use 5.
Dosing Recommendations
For adult patients with normal renal function 1:
- Standard dosing: 1 gram IV every 8 hours (infused over 15-30 minutes)
- For severe infections or Pseudomonas: Consider 2 grams every 8 hours
- Adjust for renal impairment: Reduce dose based on creatinine clearance
Important Clinical Considerations
Resistance Patterns to Avoid Confusion
The resistance to quinolones and aminoglycosides in your isolate does NOT indicate carbapenem resistance. These are separate resistance mechanisms:
- Quinolone/aminoglycoside resistance in P. stuartii can occur through efflux pumps, target modifications, or enzymatic inactivation
- Carbapenem resistance requires specific mechanisms (carbapenemases, porin loss, or metallo-β-lactamases) 1
When Meropenem May Not Be Optimal
While meropenem is appropriate here, be aware that:
- Recent surveillance data shows emerging carbapenem resistance in P. stuartii, including resistance genes to carbapenems 6
- Always verify susceptibility testing was performed correctly
- If clinical failure occurs despite documented susceptibility, consider infectious diseases consultation
Antibiotic Stewardship Perspective
For non-severe infections with P. stuartii susceptible to multiple agents, guidelines suggest considering older antibiotics to preserve carbapenems 7. However, given your isolate's resistance to quinolones and aminoglycosides (common alternatives), meropenem represents a rational choice when it demonstrates susceptibility.
Monitoring During Therapy
- CNS effects: Monitor for seizures, particularly in patients with renal impairment or CNS disorders 1
- Renal function: Dose adjustment required if creatinine clearance declines
- Clinical response: Expect improvement within 48-72 hours for most infections
- Avoid valproic acid: Meropenem significantly reduces valproic acid levels, increasing seizure risk 1
The combination of documented in vitro susceptibility, natural sensitivity patterns of P. stuartii to carbapenems, and limited alternative options due to quinolone/aminoglycoside resistance makes meropenem an evidence-based choice for this infection.